UA138819U - METHOD FOR PREDICTING THE DEVELOPMENT OF OSTEOARTHRITIS - Google Patents

Abstract

The method of predicting the development of osteoarthritis includes clinical examination and radiography. Additionally, in the patient's serum determine the polymorphism of the gene for methylenetetrahydrofolate reductase (MTHFR C677T), the content of endothelin, glycosaminoglycans (GAG), interleukin 6 (IL-6), C-reactive protein (SRP), homocysteine and 10 ng / ml, GAG> 28 μmol / l, IL-6> 10 ng / l, PSA> 6 mg / l, homocysteine> 20 μmol / l predict the development of osteoarthritis.

Description

A useful model belongs to medicine, in particular to orthopedics and rheumatology. It is prescribed and can be used in the diagnosis of the development of osteoarthritis in the early stages.

Methods of predicting the development of osteoarthritis are known. These include x-rays, studies of biopsies of the synovial membrane, synovial fluid, and cartilage biopsies

Iokorokov A.N. Diagnosis of diseases of internal organs. - M., 2001. - Vol. 2. - P. 186-196).

The disadvantage of these methods is the inability to predict the dynamics of the process in the early subclinical stages, the inability to prevent its development and possible complications due to the internal characteristics of the body.

The basis of a useful model is the task of developing a method that would allow predicting the development of osteoarthritis in the early stages.

The task is solved by the fact that, in addition to clinical examination and radiography, according to a useful model, the polymorphism of the methylenetetrahydrofolate reductase gene (MTNEV C677T), the content of endothelin, glycosaminoglycans (GAG), interleukin 6 (IL-6), C-reactive protein (SRP), homocysteine and with homozygous carrier 677-TT, endothelin content 210 ng/ml, HAG »28 μmol/l, IL-b6 »10 ng/l, SRP »6 mg/l, homocysteine 220 μmol/l are predicted development of osteoarthritis.

Application of the method. During hospitalization, the patient is examined, an X-ray is taken, and the MTNEV C677T gene polymorphism is determined. The content of endothelin, GAG, IL-6, SRP, and homocysteine is determined by the immunoenzymatic method. With homozygous carrier 677-YIT, levels of endothelin 210 ng/ml, GAG 528 μmol/l, IL-6 210 ng/l, SRP»b6 mg/l, homocysteine 220 μmol/l predict the development of osteoarthritis.

A specific example of using the method

Patient Zh., 65 years old, was hospitalized in the clinic due to the pain syndrome of the left hip joint. Examined, x-ray taken. No signs of osteoarthritis were found. Polymorphism of MTNEV C677T gene was determined in blood serum. The content of endothelin, GAG, IL-6, SRP, homocysteine was determined by immunoenzymatic method. Homozygous carrier 677-TT was established. Levels of endothelin - 24 ng/ml, GAG - 45 μmol/l, IL-6-22 ng/l, SRP - 15 mg/l, homocysteine - 42 μmol/l. The development of osteoarthritis was diagnosed. After 12 months, X-rays revealed signs of osteoarthritis.

Thus, the proposed method is informative and allows diagnosing the development of osteoarthritis at an early stage.

Claims (1)

USEFUL MODEL FORMULA The method of predicting the development of osteoarthritis, which includes a clinical examination, radiography, which is distinguished by the fact that, in addition, in the patient's blood serum, the polymorphism of the methylenetetrahydrofolate reductase gene (MTNEV C677T), the content of endothelin, glycosaminoglycans (GAG), interleukin 6 (IL-6), C-reactive protein (SRP), homocysteine and with homozygous carrier 677-TT and endothelin levels »10 ng/ml, HAG 228 μmol/l, IL-b6 »10 ng/l, SRP »6 mg/l, homocysteine 220 μmol/l predicts the development of osteoarthritis.